The significance of the question is difficult to overstate. Diagnostic labels in psychiatry are not merely administrative conveniences; they shape treatment decisions, prognosis conversations, eligibility for services, disability determinations, and the direction of a patient’s entire clinical trajectory. When a young person presents with hallucinations, delusions, disorganized thinking, or negative symptoms for the first time, clinicians face acute pressure to classify the presentation quickly. The Diagnostic and Statistical Manual of Mental Disorders, in its fifth edition, formalized the other specified schizophrenia spectrum and other psychotic disorder category precisely to accommodate presentations that are clinically significant but fall short of complete diagnostic thresholds, whether because symptom duration, symptom count, or functional decline criteria are not fully met. In practice, this category has often been treated clinically as a probable precursor to schizophrenia, a kind of pre-diagnosis that carries an implicit expectation of progression.

That expectation, the new research suggests, may be systematically wrong. By following individuals who received a first-episode diagnosis within the other specified category and tracking both their diagnostic course and their functional and symptomatic outcomes over time, the investigators assembled a longitudinal picture of what actually happens to this population. If the category were merely an early stage of schizophrenia, one would expect the majority of cases to convert to a full schizophrenia diagnosis as symptoms consolidate and duration criteria are eventually satisfied. If the category instead captured a heterogeneous mix of transient, attenuated, or genuinely atypical psychotic experiences, one would expect substantial migration in multiple directions, with many patients improving, some shifting to other spectrum diagnoses, and a minority remaining stably within the unspecified label. The study’s findings, summarized in its title as evidence for a distinct clinical entity, point toward the latter pattern, with a profile of outcomes that does not simply recapitulate the natural history of first-episode schizophrenia.

From a methodological standpoint, the study addresses one of the most persistent weaknesses in psychosis research: the tendency to exclude or lump together patients who do not fit clean diagnostic categories. Large longitudinal cohorts of first-episode psychosis frequently stratify participants by diagnosis, comparing schizophrenia, schizoaffective disorder, affective psychosis with psychotic features, and brief psychotic disorder. Patients carrying other specified diagnoses are often either folded into a residual group or dropped from analyses altogether, a practice that both inflates the apparent homogeneity of named categories and renders the most diagnostically uncertain patients invisible to science. By placing this group at the center of inquiry rather than the margin, the study recovers a population that is common in real-world clinical settings, particularly in early intervention services where careful, provisional first diagnoses are the norm.

The clinical implications of diagnostic stability data are immediate and practical. When clinicians can tell a patient and family that a given first-episode diagnosis carries a known probability of remaining stable, of resolving, or of evolving into another condition, the conversation changes from one of vague reassurance to one of quantified expectation. For the other specified category, the traditional assumption of inevitable progression toward schizophrenia has arguably generated unwarranted pessimism, potentially influencing clinicians and families to interpret ambiguous developments through the darkest available lens. A more accurate empirical picture, in which many individuals with this diagnosis do not progress to schizophrenia and may show outcomes better than typically reported for first-episode schizophrenia itself, could recalibrate prognostic communication, reduce stigma associated with the initial diagnosis, and encourage appropriately intensive but not fatalistic monitoring.

The study also speaks to a deeper theoretical tension in psychiatric nosology. Since the reliability-focused reforms of DSM-III in 1980, diagnostic categories in psychiatry have been treated as if they carve nature at its joints, yet decades of research on symptom dimensions, genetic correlations, and transdiagnostic mechanisms have repeatedly suggested that psychosis exists on continua rather than in discrete boxes. The other specified category occupies an awkward position in this debate. Critics have argued that such residual categories are nosological dustbins that undermine the validity of the system by concealing heterogeneity. Proponents counter that they honestly reflect the limits of current diagnostic science while preserving clinical flexibility. Evidence that a residual category shows internal coherence, in the form of reasonably stable diagnoses and a characteristic outcome profile, would challenge the dustbin interpretation and lend support to the possibility that some presentations currently labeled as other specified represent a genuinely identifiable syndrome that current criteria simply lack the vocabulary to name.

The distinction matters enormously for early intervention research and service design. Early intervention in psychosis programs, which have proliferated internationally and demonstrated meaningful benefits for functional recovery, typically enroll patients within a defined window after the first psychotic episode and tailor treatment intensity to expected risk. If a substantial fraction of patients carrying provisional unspecified diagnoses actually have a milder or more remitting condition, blanket application of protocols designed for schizophrenia may represent both an inefficient allocation of intensive resources and an iatrogenic risk, exposing individuals to antipsychotic treatment durations and prognostic messaging calibrated to a more severe illness than the one they have. Conversely, if a meaningful subset of these patients does deteriorate, identifying reliable early predictors of that trajectory becomes a priority. Longitudinal outcome data of the kind reported in this study provide the empirical foundation on which such stratified approaches must be built, because risk prediction is only as good as the outcome distributions it is trained to anticipate.

The findings also carry weight for the ongoing revision debates surrounding psychiatric classification. The research community preparing future editions of the DSM and the International Classification of Diseases has grappled with proposals ranging from dimensional severity ratings to wholesale reorganization of the psychosis section. Any proposal to promote, split, merge, or retire diagnostic categories ultimately depends on longitudinal evidence about stability, outcomes, and treatment response. A demonstration that the other specified schizophrenia spectrum category functions as a distinct clinical entity, rather than as an early or attenuated form of schizophrenia, would argue for either a named and criterion-defined diagnosis in future classifications or, at minimum, explicit guidance distinguishing it from the prodromal and precursor states with which it is often conflated. Classification follows evidence, and evidence of this kind is precisely what has been missing.

As with any single study, the new findings invite replication across independent cohorts, diverse health systems, and longer follow-up horizons, and they raise the familiar interpretive challenges of observational psychiatric research, including the influence of treatment on observed trajectories and the possibility that referral patterns shape who receives the unspecified label in the first place. Yet the core contribution stands on its own terms. A diagnosis long treated as an administrative compromise, a reluctant concession to diagnostic uncertainty, has been subjected to the same longitudinal scrutiny applied to schizophrenia itself and has emerged with a recognizable clinical identity. For the many patients who carry this label during the most disorienting period of their lives, and for the clinicians and families navigating that period alongside them, the message is a quietly radical one: an unspecified diagnosis is not a disguised certainty of schizophrenia, and the natural history of this condition deserves to be understood, studied, and treated on its own evidence.

Subject of Research: Clinical outcomes and diagnostic stability in first-episode other specified schizophrenia spectrum and other psychotic disorder

Article Title: Clinical outcomes and diagnostic stability in first-episode other specified schizophrenia spectrum and other psychotic disorder: evidence for a distinct clinical entity

Article References: Setiani, A., Li, L., Odkhuu, S., Kim, W.-S., Nazir, S., Starzer, M. S. K., Weibell, M., Chen, E. Y. H., Liu, C.-C., Mizuno, M., & Chung, Y.-C. (2026). Clinical outcomes and diagnostic stability in first-episode other specified schizophrenia spectrum and other psychotic disorder: evidence for a distinct clinical entity. Schizophrenia. https://doi.org/10.1038/s41537-026-00804-4

Image Credits: AI Generated

DOI: 10.1038/s41537-026-00804-4

Keywords: schizophrenia spectrum, first-episode psychosis, diagnostic stability, DSM-5, psychiatric nosology, early intervention, clinical outcomes, psychotic disorders, prognosis, longitudinal study, Clinical, outcomes

The research, conducted at Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, followed 1,059 consecutive patients, both adults and children, who were referred for biopsy between 2010 and 2022 with clinical suspicion of a lymphoproliferative disease, an umbrella term covering lymphomas and related disorders of the lymphoid tissues. Every one of these patients underwent imaging-guided core needle biopsy as their first diagnostic procedure, and the results, published in CVIR Oncology, are striking. In 96.6 percent of all referred patients, the needle biopsy alone delivered a conclusive histological diagnosis without any need for follow-up surgery. Among the 882 patients ultimately confirmed to have lymphoma, 95.9 percent received a complete, actionable diagnosis from the needle procedure alone.

Those numbers matter because of what they replace. Traditional excisional biopsy requires surgical pre-assessment, anesthesia, an incision, and recovery time, and carries risks of infection, scarring, and bleeding. It can also introduce delays at exactly the moment when speed matters most, since different lymphoma subtypes demand radically different treatment strategies, and treatment often cannot begin until the subtype is pinned down. Core needle biopsy, by contrast, is a minimally invasive procedure performed through a tiny puncture, typically under local anesthesia, in an outpatient or short-stay setting. For frail patients, for those needing urgent therapy, and for anyone with a deep-seated lesion that surgery would struggle to reach safely, the difference is not merely one of convenience but of clinical feasibility.

The technical backbone of the procedure is the semiautomated Tru-cut needle, a spring-loaded device available in gauges ranging from 14 to 18 Gauge in routine practice, with 16 Gauge being the workhorse in the Milan series. The operator pulls back a mandrel to load the spring, advances the needle into the target tissue while continuously visualizing the needle tip, and then fires the outer cutting cannula over the stylet, capturing a slender cylindrical core of tissue. At this institution, at least three or four passes through the lymph node or lesion are typically made, and the median number of samples in the recorded data was four. The cores are fixed in formalin, embedded in paraffin, stained with hematoxylin and eosin, and then classified according to the World Health Organization criteria using morphology, immunohistochemistry, and, when needed, FISH and molecular testing.

Equally important is how the target is chosen and how the needle finds its way there. Ultrasound guided the large majority of the procedures, 891 of the 1,059, and remains the technique of choice for superficial lymph nodes, soft tissues, salivary glands, liver, and kidney, thanks to its real-time visualization, low cost, and wide availability, often complemented by color Doppler mapping of the lesion’s vascular structure. Computed tomography took over for deep anatomical sites, accounting for 168 procedures, particularly retroperitoneal and mediastinal lesions nestled near vessels and organs. For these, the team used a coaxial technique, placing a larger introducer through which the biopsy needle could be advanced repeatedly, allowing multiple samples from a single puncture while reducing the risks of bleeding and tumor seeding. Contrast-enhanced CT scans helped identify viable tissue and avoid sampling necrotic or liquefied areas, and the technique proved its worth: CT-guided biopsies actually achieved a slightly higher diagnostic yield, 97.1 percent, than ultrasound-guided ones, at 95.8 percent.

A particularly sophisticated element of the workflow was the use of positron emission tomography, or PET-CT, for target selection. In 42.5 percent of lymphoma cases, a PET-CT scan performed within 30 days before the biopsy was available to guide the choice of where to sample. Because fluorodeoxyglucose uptake correlates with the histological grade and proliferative activity of lymphoma cells, hot spots on a PET image mark the metabolically active, viable regions of a tumor, allowing operators to aim the needle at the most informative tissue and steer clear of dead or fibrotic zones. The study found that PET-CT availability did not measurably raise the overall binary diagnostic yield, but the authors argue that its true value is qualitative: distinguishing active disease from post-treatment fibrosis, and selecting the clinically most informative target in cases of suspected relapse or transformation. In one illustrative case, a retroperitoneal mass showed poor enhancement on contrast CT, yet PET imaging revealed intense uptake in the same region, and the needle was placed precisely where the PET signal was strongest, yielding a conclusive diagnosis that conventional imaging alone might have missed.

Safety was another standout finding. Not a single patient in the entire cohort suffered a biopsy-related complication of grade 2 or higher on the standard CTCAE v5 scale, meaning no severe bleeding, infection, or event requiring unplanned intervention. Minor local bleeding occurred in roughly 5 percent of cases, and no patient required hospitalization beyond the planned 24 hours after deep-tissue biopsies. Standard precautions, including blood counts and coagulation testing, stopping anticoagulation at least 24 hours before the procedure, and platelet transfusion for patients with counts below 50,000 per microliter, kept the risk profile firmly in check. Even the 22 pediatric patients in the cohort were managed successfully, underscoring that minimally invasive image-guided biopsy can be appropriate even in children when multidisciplinary teams weigh anesthetic risk, lesion location, and protocol requirements.

The study is honest about where the needle falls short. Thirty-six lymphoma patients, 4.1 percent of the cohort, still required a subsequent excisional biopsy, either because the needle sample was inadequate or because it was suggestive but not conclusive. Notably, certain subtypes were overrepresented in this surgical group: half of the patients with nodular lymphocyte-predominant Hodgkin lymphoma and 15 percent of those with peripheral T-cell lymphoma needed surgery to reach a final diagnosis, a pattern consistent with pathological guidance suggesting that these entities are best assessed when an entire lymph node’s architecture can be examined. Among the 36 surgical cases, the excisional diagnosis differed from the needle-based impression in 9 patients, confirmed it in 12, and provided a new conclusive answer in 15, all of whom ended up with a definitive histological result. The authors stress that these figures argue not against needle biopsy, but for prompt surgical follow-up whenever the needle result does not inspire confidence for treatment decisions, ideally after early multidisciplinary discussion among hematologists, radiologists, and pathologists.

The broader picture emerging from more than a decade of data is one of a diagnostic landscape in transition. The Lugano classification, the standard framework for lymphoma management, still reserves core needle biopsy for situations where surgery is not possible or for relapse. Yet this Milanese experience, one of the largest single-center intent-to-diagnose cohorts ever assembled, shows that with careful patient selection, meticulous imaging guidance, judicious needle gauge choice tailored to lesion location, multiple sampling, and PET-informed targeting, the needle succeeds where the scalpel was once thought indispensable. Follicular lymphoma, diffuse large B-cell lymphoma, and classical Hodgkin lymphoma, the three most common diagnoses in the cohort, were reliably captured by needle sampling, and 177 patients with suspected lymphoma actually turned out to have entirely different conditions, including metastatic carcinoma, sarcoma, neurogenic tumors, and retroperitoneal fibrosis, all of which the needle correctly identified. In an era when medicine increasingly prizes precision with minimal invasiveness, this study makes a compelling case that for most patients with suspected lymphoma, the first and often only diagnostic procedure needed is one that fits through a needle’s eye.

Subject of Research: Diagnostic yield and procedural techniques of imaging-guided core needle biopsy in patients with suspected lymphoproliferative disease

Article Title: Core needle biopsy in patients with suspected lymphoproliferative disease: diagnostic yield in a large single-center cohort and procedural techniques

Article References: Core needle biopsy in patients with suspected lymphoproliferative disease: diagnostic yield in a large single-center cohort and procedural techniques. (n.d.). https://doi.org/10.1007/s44343-026-00051-5

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00051-5

Keywords: core needle biopsy, lymphoma, lymphoproliferative disease, excisional biopsy, ultrasound-guided biopsy, CT-guided biopsy, PET-CT, interventional radiology, diagnostic yield, hematologic malignancies, Tru-cut needle, minimally invasive diagnosis

The stakes could hardly be higher. Breast cancer remains the second most common malignancy among women worldwide, with roughly 2.3 million new cases diagnosed in 2022 according to global cancer statistics. In China alone, an estimated 357,000 women were diagnosed and 75,000 died from the disease that year. Between 20 and 30 percent of these tumors carry amplification of the human epidermal growth factor receptor 2 gene, a molecular driver that fuels aggressive tumor initiation, invasion, and proliferation. Thanks to modern anti-HER-2 therapies, patients whose tumors overexpress this protein now fare far better than they did two decades ago, but the choice of chemotherapy backbone paired with those targeted agents still matters enormously.

Paclitaxel has long been a cornerstone of breast cancer chemotherapy. As a taxane, it works by stabilizing microtubules, inhibiting the depolymerization of tubulin and promoting polymerization, thereby arresting mitosis and suppressing tumor cell proliferation. Yet conventional solvent-based formulations carry a well-known pharmacological liability: they rely on polyoxyethylated castor oil and anhydrous ethanol as vehicles. The castor oil derivative can activate mast cells to release histamine, triggering severe hypersensitivity reactions that require routine corticosteroid premedication. Worse, the solvent forms micellar complexes with paclitaxel in the bloodstream, limiting tissue penetration and potentially blunting antitumor efficacy. Liposomal encapsulation within phosphatidylcholine sidesteps both problems, enhancing drug stability, prolonging retention and effective half-life in the body, and eliminating solvent-related toxicities.

Despite landmark trials such as H0648g, M77001, and CLEOPATRA establishing taxane plus anti-HER-2 therapy as the standard first-line approach, robust evidence on paclitaxel liposome specifically had been lacking. To close that gap, investigators turned to the National Cancer Center Oncology Information Database, the largest oncology database in China, spanning more than 2,000 hospitals across 31 provinces and approximately 22 million cancer patients since 2013, with mortality data integrated from the national death registry. From this resource, they identified 526 patients with unresectable locally advanced or metastatic HER-2-positive breast cancer who received paclitaxel liposome combined with anti-HER-2 agents as first-line salvage therapy between January 2013 and December 2022.

The cohort, with a median age of 53 years and 56.3 percent hormone receptor-positive disease, reflects the messiness of real-world oncology. Just over half of patients, 53.2 percent, received paclitaxel liposome plus trastuzumab, the workhorse monoclonal antibody that binds the HER-2 receptor’s extracellular domain. Another 32.1 percent received triple therapy with trastuzumab and pertuzumab, which blocks receptor dimerization and delivers dual blockade of HER-2 signaling. A further 11 percent combined trastuzumab with small-molecule tyrosine kinase inhibitors. Before treatment, a third of patients had bone metastases, roughly 30 percent had lung metastases, and 23 percent had liver involvement, while 58.6 percent had disease confined to a single organ. Notably, 75.9 percent had never received a taxane in the earlier treatment setting, making them ideal candidates for first-line salvage therapy with the liposomal agent.

The efficacy numbers were striking. After a median follow-up of 856 days, the overall median real-world progression-free survival reached 22.1 months, with one-, two-, three-, and five-year progression-free rates of 72.1, 46.7, 34.0, and 21.0 percent respectively. Median overall survival extended to 57.9 months, an exceptional figure for metastatic disease, with 97.2 percent of patients alive at one year and nearly half surviving five years. The objective response rate stood at 55.9 percent, and disease control, encompassing complete responses, partial responses, and stable disease, reached a remarkable 94.7 percent. Hormone receptor-positive patients fared best, with median progression-free survival of 24.5 months and overall survival of 60.5 months, compared with 17.7 and 53.5 months in hormone receptor-negative patients, evidence that the regimen delivers substantial benefit regardless of hormone receptor status.

Digging deeper into treatment combinations revealed clinically meaningful differences. Patients on paclitaxel liposome plus trastuzumab alone achieved a median progression-free survival of 17.2 months, while those receiving dual blockade with pertuzumab reached 33.3 months, an unsurprising but welcome confirmation that blocking HER-2 through two independent mechanisms deepens disease control. The kinase inhibitor combination produced 21.9 months. Interestingly, median overall survival was numerically longer in the trastuzumab-only group, 59.1 versus 49.9 months for dual blockade, a paradox the authors attribute to confounding by indication: pertuzumab was not reimbursed nationally during much of the study period, so clinicians reserved the intensive dual-blockade regimen for patients with higher tumor burdens and more aggressive disease. Multivariable analysis confirmed that dual blockade was itself an independent protective factor, cutting the hazard of progression roughly in half, while having two or more metastatic sites doubled the risk of both progression and death.

Safety data reinforced the formulation’s pharmacological advantage. Myelosuppression, the expected paclitaxel-related bone marrow suppression, occurred in 34.8 percent of patients, and gastrointestinal reactions in 18.4 percent, while hepatic dysfunction and neurotoxicity each remained below 5 percent. No new safety signals emerged. Critically, the liposomal delivery system eliminated the hypersensitivity risk that defines solvent-based paclitaxel, sparing patients the steroid premedication and infusion reactions that complicate conventional taxane administration. Treatment adherence was correspondingly strong: 81.4 percent of patients completed therapy at full dose, 64.4 percent finished the planned course, and another 14.3 percent continued the drug as maintenance, with only 2.3 percent discontinuing due to intolerance.

The authors are candid about the limitations inherent to retrospective, registry-based research. Physician-determined progression assessments were not subjected to independent central imaging review, performance status was unrecorded for 42.8 percent of patients, incomplete adverse event documentation prevented detailed toxicity grading, and the database did not capture granular HER-2 expression patterns or paired pathology from primary and metastatic lesions. Regional differences in response assessment may also explain why the objective response rate, while solid, trails that of some randomized trials, a discrepancy partly explained by the high proportion of bone-only metastases, which often manifest as stable disease rather than measurable shrinkage under RECIST 1.1 criteria. Still, the overall picture aligns closely with the CLEOPATRA and PHILA trials, and the study stands as the largest real-world analysis of first-line treatment for HER-2-positive advanced breast cancer in China to date, suggesting that paclitaxel liposome deserves a firm place alongside, and perhaps in preference to, solvent-based taxanes in global treatment guidelines.

Subject of Research: Paclitaxel liposome combined with anti-HER-2 targeted drugs as first-line therapy for recurrent or metastatic HER-2-positive breast cancer in a real-world setting.

Article Title: Paclitaxel liposome with anti–HER-2 drugs as first-line therapy for recurrent/metastatic HER-2–positive breast cancer: a real-world study

Article References: Paclitaxel liposome with anti–HER-2 drugs as first-line therapy for recurrent/metastatic HER-2–positive breast cancer: a real-world study. (n.d.). https://doi.org/10.1007/s44178-026-00283-8

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00283-8

Keywords: paclitaxel liposome, HER-2-positive breast cancer, trastuzumab, pertuzumab, real-world study, progression-free survival, overall survival, targeted therapy, chemotherapy, metastatic breast cancer, drug delivery, oncology

Researchers at Dongguan Maternal and Child Health Care Hospital in China retrospectively analyzed 99 children born small for gestational age who had either failed to show catch-up growth, presented with multisystem anomalies, or both. Using trio-based whole-exome sequencing, in which the affected child and both parents are sequenced together, the team searched for the genetic roots of these children’s conditions. The results were striking: a confirmed molecular diagnosis was established in 59 of the 99 children, a diagnostic yield of 59.6 percent.

Trio-based whole-exome sequencing works by capturing and reading the protein-coding portions of the genome—the exome—in all three members of a family. Because the parents’ sequences are available for comparison, scientists can determine whether a suspicious variant was inherited from a carrier parent or arose spontaneously in the child. This segregation analysis is critical for interpreting variants correctly, since the same DNA change can be harmless in one context and disease-causing in another.

The study’s methodology went beyond simple sequence analysis. In addition to examining single-nucleotide and small insertion-deletion variants, the researchers mined the sequencing read-depth data to infer copy-number variants—large deletions or duplications of chunks of chromosomes that conventional exome pipelines often miss. Sequence variants were confirmed by Sanger sequencing, the older but highly accurate method of reading individual DNA fragments. Variants were then classified using the standards developed by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology for sequence variants, and the ACMG/ClinGen criteria for copy-number variants.

Only pathogenic or likely pathogenic findings whose inheritance pattern fit the family data were counted as molecular diagnoses. This conservative approach matters in clinical genetics, where over-interpretation of ambiguous variants can lead to false diagnoses. The team also identified four variants that remained classified as variants of uncertain significance—changes that could not be confidently labeled benign or disease-causing and therefore did not count toward the diagnostic yield.

Breaking down the 59 diagnoses, the researchers found considerable diversity in the underlying genetic architecture. Monogenic disorders—single-gene defects—accounted for the largest share, explaining 44 children, or 74.6 percent of the diagnosed cases. Copy-number variants explained 13 children, or 22.0 percent. Notably, two children received dual diagnoses, carrying both a disease-causing sequence variant and a pathogenic copy-number variant, a reminder that a single genetic explanation is not always sufficient.

The diagnostic yield differed meaningfully between the two clinical presentations. Among children with isolated failed catch-up growth—those born small who never caught up but had no other anomalies—trio-WES produced a diagnosis in 52.9 percent of cases, or 9 of 17 children. Among children with multisystem anomalies, the yield rose to 61.0 percent, or 50 of 82 children. The higher yield in the multisystem group aligns with genetic principles: when developmental disturbances affect multiple organ systems, a shared underlying genetic cause becomes more likely, and the genome search has more clinical features to anchor interpretations.

The clinical implications are considerable. A molecular diagnosis does more than attach a name to a condition. It can redirect management toward condition-specific surveillance and treatment, inform parents about recurrence risks for future pregnancies, and spare families a prolonged diagnostic odyssey of repetitive and often invasive testing. For children born small for gestational age, identifying a specific genetic syndrome may reveal risks—such as endocrine dysfunction, renal anomalies, or tumor predisposition—that would otherwise be missed. Genetic counselling grounded in an identified inheritance model allows clinicians to tell parents precisely whether the condition could recur in a subsequent child.

The authors are careful to draw boundaries around their conclusions. The 99 children in this study were not a random sample of all children born small for gestational age; they were a clinically selected, high-risk subgroup who had already raised concern because of persistent growth failure or anomalies affecting multiple systems. The researchers explicitly caution that the 59.6 percent diagnostic yield should not be generalized to the overall SGA population, most of whom are simply constitutionally small and healthy. Applying expensive genome-wide testing to every child born small, without clinical red flags, would produce far lower yields and risk incidental and ambiguous findings.

Still, the study adds to a growing body of evidence that trio-based genomic sequencing should be considered early rather than late in the evaluation of children with unexplained growth failure and congenital anomalies. As sequencing costs continue to fall and analytical tools improve—including methods that detect copy-number variants from exome data without separate chromosome microarray testing—the case for a single comprehensive genetic test at the start of the diagnostic journey grows stronger. For families facing the anxiety of a child who is not growing as expected, a faster path to answers may now be within reach.

Subject of Research: Use of trio-based whole-exome sequencing to diagnose genetic disorders in children born small for gestational age with failed catch-up growth or multisystem anomalies

Article Title: Clinical application of trio-based whole-exome sequencing in children born small for gestational age with failed catch-up growth or multisystem anomalies

Article References: Jiang, Z., Zhong, X., Lin, P., Yan, T., He, W., Guo, L., Xie, Y., Yuan, H., & Cheng, S. (2026). Clinical application of trio-based whole-exome sequencing in children born small for gestational age with failed catch-up growth or multisystem anomalies. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07633-5

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07633-5

Keywords: small for gestational age, trio whole-exome sequencing, failed catch-up growth, multisystem anomalies, molecular diagnosis, copy-number variants, genetic counselling, pediatrics, next-generation sequencing, rare variants, clinical genetics, Clinical

The authors build their case from a series of revealing examples drawn from British screening history. The UK National Screening Committee recommended against population-based prostate cancer screening, concluding that while screening prevented prostate cancer deaths, it also caused harm through overdiagnosis and overtreatment, leaving some men with urinary incontinence or erectile dysfunction. In reaching that conclusion, the committee made a value judgement about how to weigh extended life against morbidity — and, the authors note, it assumed without evidence that individual men would share its values. Meanwhile, when Wales extended the cervical screening interval for women aged 25 to 49 from three years to five in 2022, a scientifically defensible decision triggered a public outcry and a petition signed by more than a million people, prompting England to delay the same change until July 2025.

Bowel screening illustrates how resources quietly shape supposedly clinical thresholds. The faecal immunochemical test, or FIT, applies a binary cut-off to the amount of blood in a stool sample, and that cut-off ranges from 8.5 to 150 micrograms of haemoglobin per gram of faeces across programmes, largely to manage colonoscopy capacity. Historically, Wales used a threshold of 150, England 120 and Scotland 80 micrograms per gram — meaning a result deemed normal in England could have triggered a colonoscopy just across the Scottish border. The stakes of delay are also stark: randomised trials showed guaiac-based faecal occult blood testing reduced colorectal cancer mortality as early as 1996, yet England’s screening programme only completed roll-out in 2010. Screening now prevents roughly 2,000 colorectal cancer deaths annually in England; had it rolled out in 2000, the authors estimate some 20,000 premature deaths could have been averted.

To make sense of such cases, Sasieni and John adapt five principles for decision-making under uncertainty — proportionality, justice, autonomy, feasibility and adaptability — into a framework specifically for cancer screening. Their central claim is that policymakers suffer from an asymmetry of fear: they worry intensely about false-positive decisions, such as introducing a screening programme that turns out to do more harm than good, while largely ignoring false-negative decisions, in which beneficial programmes are delayed or withheld. Because committees periodically revisit recommendations, a cautious ‘not yet’ feels reversible and safe. But delay has consequences that can be quantified even without certainty. If prostate screening in men aged 50 to 65 reduces prostate cancer mortality by 25 percent over 15 years, a two-decade implementation delay could translate into around 20,000 avoidable deaths in the UK. Conversely, had multimodal ovarian cancer screening been introduced for women aged 50 to 74 before the definitive UKCTOCS trial results, roughly 7,000 women each year might have undergone unnecessary surgery. Both sides of the ledger can be estimated, the authors argue, and should be before decisions are made.

The principle of justice exposes another hidden cost of slowness: inequality. Wealthy and well-educated people frequently obtain screening privately long before public programmes roll out. In the United States, colonoscopy use is 50 percent higher in the wealthiest socioeconomic quintile than in the poorest. In England, prostate-specific antigen testing is 25 percent lower in the most deprived quintile — and metastatic prostate cancer rates there are 11 percent higher, while overall prostate cancer incidence is 19 percent lower, plausibly reflecting inequitable access to asymptomatic PSA testing. Justice also complicates the details: some researchers argue FIT referral thresholds should differ for women and men, but the right answer depends on which measure of equity one chooses to prioritise, a value judgement that should be made transparently. Even overdiagnosis falls unevenly — introducing prostate screening for men in their seventies would generate more overdiagnosis among the most deprived, whose shorter life expectancy means more of them die of other causes before screening could ever help.

Autonomy poses a deeper philosophical problem. Public health typically overrides individual preferences for the collective good, while clinical medicine demands informed consent. Screening sits awkwardly between: society seeks consent before screening anyone, yet takes a paternalistic stance on what screening is offered at all, rarely considering the ethics of denying screening to those who want it. The authors suggest a more democratic division of labour, inspired by the Dutch model: expert committees could summarise evidence and uncertainties without issuing recommendations, forcing elected politicians to make the value-laden choices explicitly. Where experts disagree, politicians should decide. They even sketch a personalised option for prostate screening — inviting men aged 50 to 69 for triennial PSA testing without encouraging participation, letting personal risk tolerance guide the decision, much as oncology patients weigh their own treatment choices.

Feasibility, the authors stress, already governs screening policy whether it is admitted or not. FIT thresholds and age ranges are set by colonoscopy capacity; MRI-based prostate screening would demand vast new infrastructure of scanners and staff; and in low- and middle-income countries, cervical screening is constrained by the lack of facilities to triage screen-positive women and treat precancerous lesions. Public opinion constrains policy too — hence the continued offering of cervical screening at age 25 to women vaccinated against HPV as adolescents, despite their extremely low cervical cancer risk and the likelihood that screening does them more harm than good. The authors argue the public is mature enough to understand these trade-offs, provided they are communicated honestly.

Adaptability may be the most urgent principle in an era of artificial intelligence and liquid biopsies. Traditional screening trials are ruinously expensive — the National Lung Cancer Screening Trial cost 256 million dollars in 2002, roughly 400 million today — and a binary framework of full national implementation or complete rejection leaves no pathway for pragmatic pilots that generate evidence while delivering benefit. Multicancer detection tests sharpen the dilemma: by the time one test’s clinical utility is fully evaluated, the technology will be outdated, and trial designs that test each cancer type separately would require randomising millions of people. The authors call for publicly funded pilots designed to fill evidence gaps, with implementation beginning in health-deprived regions to address injustice rather than widen it. They are candid about the risks of permissiveness — a pilot ovarian screening programme before 2021 would have harmed some healthy women with false positives — but insist those harms and benefits could and should have been estimated in advance, and that any new decision-making system should itself be monitored and reformed if it fails.

The paper’s conclusion is disarmingly simple: presenting screening policy as a straightforward application of evidence-based medicine obscures profound ethical and political choices, and delaying a decision is itself a decision against change — one measured in preventable deaths, avoidable morbidity and widening inequality. As AI begins to exceed human radiologists and pathologists, quantifying future disease risk and optimising screening intervals, governance structures built around static population interventions and decade-long trials will be unable to evaluate products superseded every five years. Who decides, on what basis, and how quickly — the authors argue — are questions that can no longer be left unasked.

Subject of Research: Ethical and policy frameworks for cancer screening decision-making under uncertainty

Article Title: The clinical consequences of excessive caution: rethinking how cancer screening policy is made

Article References: Sasieni, P., & John, S. (2026). The clinical consequences of excessive caution: rethinking how cancer screening policy is made. eClinicalMedicine, Article 104188. https://doi.org/10.1016/j.eclinm.2026.104188

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104188

Keywords: cancer screening, screening policy, decision-making under uncertainty, health inequalities, prostate cancer screening, bowel cancer screening, multicancer detection tests, artificial intelligence, overdiagnosis, public trust, clinical, consequences

Malignant ascites, the pathological accumulation of fluid within the peritoneal cavity driven by cancer involving the peritoneal membrane, increased vascular permeability, or lymphatic blockage, accounts for roughly 10 to 15 percent of all ascites cases and carries a poor prognosis. The condition produces a cascade of debilitating symptoms: abdominal fullness and bloating, pain, nausea, difficulty breathing, reduced mobility, and loss of appetite, all of which erode quality of life at a stage when patients and their families have limited time together. Unlike ascites caused by cirrhosis or heart failure, dietary modification and diuretics tend to be ineffective in the malignant form, leaving fluid evacuation as the mainstay of palliative treatment.

Repeated large-volume paracentesis addresses the symptom but never the underlying cause, so the procedure must be performed regularly, at considerable cost to both patients and health systems and with a cumulative risk of procedural complications. Tunneled indwelling peritoneal catheters, or IPCs, have emerged as an alternative that allows drainage at home. The United Kingdom’s National Institute for Health and Care Excellence approved first-generation devices as cost-effective in 2012 and reaffirmed that judgment in 2022, but many supporting studies involved small patient numbers, and clear criteria identifying which patients are most likely to benefit have been lacking.

The new analysis, led by Krasen Zdravkov Ivanov of University Hospital Saint Ekaterina in Sofia, Bulgaria, together with Hans-Ulrich Laasch of the University of Manchester, examined a large single-center cohort treated with a second-generation device. Patients were eligible if their ascites required at least two drainage procedures per month. Exclusion criteria included active peritoneal infection, deranged clotting with an INR above 1.8 or platelet counts below 50,000 per microliter, loculated ascites, an ECOG performance status of 4 with estimated survival under three weeks, and known allergy to catheter components. Every patient underwent history and physical examination, laboratory testing, and abdominal ultrasound at least 48 hours before implantation.

The technical details of the procedure are central to its success. The Aspira catheter is a 15.5-French, 72-centimeter fenestrated silicone tube with 50 drainage holes on its intraperitoneal end. A single experienced interventionalist performed all insertions using an antegrade tunneling technique under sterile conditions, with local anesthesia and perioperative intravenous ceftriaxone. After ultrasonography identified an implantation site away from scars, tumor masses, bowel, and other organs, typically in the iliac fossa, a subcutaneous tunnel of roughly five to eight centimeters was fashioned, the abdominal cavity was punctured under ultrasound guidance, and a peel-away sheath fitted with a leakage-preventing valve was placed over a guidewire. Correct positioning of the catheter tip in the pelvis was confirmed with ultrasound or X-ray. Technical success was achieved in all 124 patients without exception.

The cohort, with a mean age of 60.6 years and a strong female majority at 67.7 percent, reflected the typical epidemiology of malignant ascites: ovarian cancer was the most common primary malignancy at 19.4 percent, followed by breast cancer at 18.5 percent and colon cancer at 14.5 percent. Adenocarcinoma accounted for more than three-quarters of tumor types, peritoneal carcinomatosis was the leading mechanism at 42.7 percent, and the fluid was predominantly an exudate. Nearly three-quarters of patients were actively receiving chemotherapy, radiotherapy, or immunotherapy, while the remainder were on supportive or palliative care.

Symptom outcomes were striking. Using the Edmonton Symptom Assessment System modified for ascites, researchers found statistically significant improvement in every symptom measured at 30 days, including pain, general weakness, nausea, depression, anxiety, drowsiness, appetite, sense of well-being, shortness of breath, abdominal bloating, and impaired mobility, all with p-values below 0.001. The largest average changes were in abdominal bloating, which improved by 8.1 points on the 10-point scale, impaired mobility by 6.3 points, and pain by 6.0 points. Significant improvements in fluid-volume symptoms such as shortness of breath and bloating persisted at 90 days, although anxiety, appetite, well-being, and mobility gains were no longer statistically significant at that point, a pattern the authors attribute partly to cancer progression and the side effects of ongoing anticancer therapy. The mean number of hospital visits fell by 45.4 percent between the 30-day and 90-day periods, from 1.1 to 0.6 per interval. The mean duration of catheter use was 103.3 days.

Safety results were also reassuring. Twenty-six patients, or 21.0 percent, experienced catheter-related complications, but most were minor and easily managed. These included cellulitis in seven patients treated successfully with antibiotics, ascites leakage at the implantation site within 48 hours in five patients corrected with sutures, valve defects in two patients whose valves were replaced without removing the catheter, and subcutaneous hematomas in two patients. Ten complications, or 8.1 percent, were classified as moderate because they required catheter removal: one device obstruction from adjacent tumor overgrowth, one dislocation, and eight cases of secondary bacterial peritonitis. All patients recovered after systemic antibiotics or device replacement, and no infection-related deaths occurred. Notably, patients with serous and fibrinous ascites fluid experienced complications more frequently, an observation that may help guide aftercare intensity.

Beyond the numbers, the study’s practical contribution is a treatment algorithm to help clinicians select candidates most likely to benefit, an area where formal guidelines have been notably absent. The authors emphasize that adequate control of ascites symptoms can determine whether a patient is well enough to continue treatment for the underlying malignancy, and that reliable home drainage helps patients return home sooner and spend quality time with loved ones. They also highlight device-specific advantages, including a valve system that nearly eliminates fluid spillage during implantation, an infection control benefit as well as a slip hazard reduction, the option of retrograde tunneling to improve cuff fixation, and repairability that avoids removal and reinsertion in cases of accidental damage.

The authors acknowledge the limitations of a single-center, retrospective, non-comparative design, and note that the number of patients with quality-of-life data declined at 90 days. Nevertheless, they conclude that tunneled indwelling peritoneal catheters combine a high rate of technical success, durable clinical benefit, and manageable complications, offering physicians an effective, cost-conscious approach to caring for one of the most vulnerable populations in oncology.

Subject of Research: Clinical outcomes of tunneled indwelling peritoneal catheters for malignant ascites palliation

Article Title: Clinical outcomes following insertion of second-generation (Aspira®) tunneled indwelling peritoneal catheters to treat malignant ascites

Article References: Ivanov, K. Z., & Laasch, H.-U. (2026). Clinical outcomes following insertion of second-generation (Aspira®) tunneled indwelling peritoneal catheters to treat malignant ascites. CVIR Oncology, 2(1), Article 16. https://doi.org/10.1007/s44343-026-00047-1

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00047-1

Keywords: malignant ascites, peritoneal catheter, palliative care, paracentesis, oncology, interventional radiology, quality of life, catheter complications, Aspira drainage system, cancer symptoms, peritoneal carcinomatosis, Clinical

The research, led by Mauranne Lievens of the Department of Oral & Maxillofacial Surgery at Ghent University Hospital, together with Wim Van Paepegem, Tom Goffin, Geert Villeirs and Renaat Coopman, addresses a long-standing gap in the validation of hospital 3D printing programs. Earlier validation studies typically relied on geometric calibration artifacts, standardized test shapes, or simplified phantom objects—objects that behave well on a build plate but share little with the irregular, thin-walled, undercut-rich anatomy of a human skull. The Ghent team instead designed the study around highly accurate anatomical models, deliberately mimicking the actual workflow a hospital follows when a surgeon requests a patient-specific replica for preoperative planning, implant shaping, or patient counseling.

Accuracy in this context is not a single number but a composite of two distinct properties. The first is trueness, which measures how closely a printed model matches the digital reference design—the deviation between the physical object and the source file that clinicians use. The second is precision, which captures reproducibility: how consistent a printer is when producing the same model repeatedly within a single build (intra-build variability), and how consistent it is across separate print jobs run at different times (inter-build variability). Both dimensions matter clinically. A printer that faithfully reproduces anatomy once but drifts between builds is as problematic as one that is consistently wrong. The team quantified both using root mean square (RMS) error, a standard metric that aggregates surface deviation across the entire model rather than relying on a handful of caliper measurements at convenient points.

The statistical design of the study is one of its most notable contributions. Because the dataset comprised repeated prints of multiple anatomical models at multiple timepoints, the observations were inherently clustered—prints from the same build and models from the same printer are not independent of one another. Conventional statistical tests that ignore this structure can overstate significance. To handle the complexity, the researchers employed a Linear Mixed Model (LMM), a framework widely used in agriculture, ecology and clinical trials but, according to the authors, never before applied in 3D printing accuracy research. The mixed model allowed the team to evaluate fixed effects—printer type, anatomical model, and comparison type—while correctly accounting for the internal clustering of repeated measurements, yielding a statistically robust picture of where true differences lie.

The headline result is that every technology tested achieved accuracy within clinically acceptable limits, an encouraging finding for hospitals that have invested in lower-cost equipment. But the ranking was clear and statistically significant. Material Jetting, which builds objects by jetting tiny droplets of photopolymer in extremely thin layers, achieved a mean RMS error of 67 micrometers—the finest accuracy in the study. Stereolithography, which cures liquid resin layer by layer with a light source, followed at 109 micrometers. Fused Filament Fabrication, the thermoplastic extrusion process behind most affordable desktop printers, came in at 130 micrometers. In practical terms, these differences span roughly the width of one to two human hairs, yet in surgery that margin can matter: when a model is used to pre-bend titanium plates or rehearse the osteotomy of a complex orbital or mandibular reconstruction, sub-millimeter deviations propagate directly to the operating table.

Just as important as the ranking was what the Linear Mixed Model revealed about the drivers of error. Printer type was a significant fixed effect, confirming that the technology choice itself—not random variation—explains much of the accuracy difference. But anatomical complexity also exerted a significant influence, meaning that the shape being printed matters nearly as much as the machine printing it. Models with delicate facial structures, thin bony walls and deep undercuts stressed each technology differently: resin- and jetting-based photopolymer processes handled fine detail more gracefully, while extrusion-based FFF showed characteristic stair-stepping and filament-path limitations on curved, intricate surfaces. This interaction underscores why calibration artifacts alone cannot predict clinical performance; a flat test coupon tells a hospital little about how a printer will cope with a zygomatic arch or a thin orbital floor.

The study’s framing around the Medical Device Regulation gives it particular weight for European hospitals. MDR 2017/745 classifies many in-house manufactured products as devices and requires health institutions to demonstrate that their production, under the responsibility of a single legal manufacturer, meets safety and performance expectations—including verification of accuracy appropriate to the intended clinical use. Point-of-care 3D printing has often grown organically inside surgical departments, with validation practices varying wildly from one hospital to the next. By defining accuracy through trueness and precision, quantifying it with RMS error against digital references, and analyzing it with a defensible statistical model, the Ghent team has effectively published a template for the kind of documented, reproducible validation that regulators and hospital quality officers can build upon.

For hospital administrators weighing procurement decisions, the results offer a nuanced cost-benefit picture. Material Jetting’s superior fidelity comes with higher machine and material costs, and photopolymer processes require resin handling and post-processing protocols. FFF remains the most affordable and accessible option, and the study confirms its output is still clinically acceptable—suggesting it can retain a role for models where extreme fidelity is not essential, such as patient education or approximate planning. SLA sits between the two, offering strong performance at moderate cost. The finding that all three cleared the clinical acceptability bar means the choice can legitimately be driven by the intended application, budget and workflow, rather than by fear that cheaper technology is automatically unsafe. For applications demanding the highest anatomical fidelity within the MDR framework, however, the evidence now points decisively toward Material Jetting.

The research also carries implications well beyond craniomaxillofacial surgery. In-house and point-of-care 3D printing is expanding rapidly into orthopedics, cardiothoracic surgery, dental applications and surgical training, and virtually every one of those programs faces the same questions: how accurate is our printer, how repeatable is it, and can we prove it? The study’s methodological chain—realistic anatomical models, digitized reference comparisons, RMS-based quantification of trueness and precision, and mixed-model statistics that respect the structure of repeated manufacturing data—offers a portable blueprint for any institution seeking to validate its own fleet. The authors note it is the first application of a Linear Mixed Model in this field, and if the approach is adopted broadly, it could standardize how hospitals across jurisdictions demonstrate regulatory compliance. Published open access in the journal 3D Printing in Medicine, with no specific external funding and no declared competing interests, the study was reviewed with the involvement of the Ghent University Hospital Medical Ethics Committee, receiving official approval on July 2, 2024, and received on 16 September 2025, accepted on 16 August 2026, and published on 11 September 2026.

Subject of Research: Comparative accuracy of FFF, SLA and Material Jetting 3D printing for in-house anatomical models in craniomaxillofacial surgery

Article Title: Clinical relevance of accuracy in in-house 3D printing in craniomaxillofacial surgery: a comparative study of FFF, SLA, and MJ technologies

Article References: Lievens, M., Van Paepegem, W., Goffin, T., Villeirs, G., & Coopman, R. (2026). Clinical relevance of accuracy in in-house 3D printing in craniomaxillofacial surgery: a comparative study of FFF, SLA, and MJ technologies. 3D Printing in Medicine. https://doi.org/10.1186/s41205-026-00344-8

Image Credits: AI Generated

DOI: 10.1186/s41205-026-00344-8

Keywords: 3D printing, craniomaxillofacial surgery, anatomical models, FFF, SLA, Material Jetting, Medical Device Regulation, accuracy validation, Linear Mixed Model, point-of-care manufacturing, Clinical, relevance

The appeal of AI in this setting rests on a simple asymmetry. Clinical trials generate enormous volumes of structured and unstructured data—imaging, laboratory values, genomic profiles, clinician notes, wearable-device streams and patient-reported outcomes—yet historically only a small fraction of that information has been used systematically in trial design and conduct. Machine-learning models, particularly modern deep-learning and foundation-model architectures, excel at extracting signal from exactly these high-dimensional, heterogeneous datasets. When trained on curated clinical data, they can identify which patient subpopulations are most likely to respond to a therapeutic candidate, predict which sites will struggle with recruitment, flag data inconsistencies long before database lock, and estimate the probability that an ongoing trial will meet its primary endpoint. The result is a shift from retrospective, intuition-driven trial management toward a prospectively optimised, continuously adaptive process.

Patient recruitment illustrates the potential most vividly. Failed recruitment and poor participant retention are among the leading reasons that trials miss their timelines or terminate early. Traditional approaches rely on broad eligibility criteria, manual chart review and outreach from a limited number of academic centres, which systematically under-enrols patients from rural areas, lower-income communities and historically marginalised groups. AI-driven approaches invert this model. Natural-language processing systems can scan millions of de-identified electronic health records to locate every patient matching a complex eligibility profile, including patients whose relevant conditions are described only in free-text notes rather than coded diagnoses. Matched patients can then be connected with trial sites through their treating physicians or through decentralised trial infrastructure that brings the study to the participant rather than the reverse. When designed carefully, such tools can also be tuned to improve diversity in enrolment, addressing a long-standing scientific weakness as well as an ethical one: a trial population that does not resemble the eventual treated population limits the generalisability of the results.

Trial design itself is being recomputed. Classical phase II and phase III trials typically use fixed designs conceived months before enrolment begins, and any mid-course revision requires protocol amendments that can delay readouts by many months. AI-assisted design tools draw on large repositories of historical trial outcomes, natural-history data and simulation frameworks to model, before a single patient is enrolled, how a trial will behave under different assumptions about effect size, dropout, endpoint variability and site performance. Bayesian adaptive designs, which allow the randomisation ratio and dose allocation to shift as interim data accumulate, become far more practical when machine-learning models supply reliable predictive components. Digital twins—computational replicas of individual patients built from rich baseline data—offer an emerging complement, allowing a portion of the control information in a trial to be estimated rather than observed, and thereby reducing the number of real participants who must be randomised to achieve a given statistical power. Regulators have begun engaging with these methods, and several external control arms constructed from historical or registry data have already supported regulatory submissions in rare-disease oncology.

Once a trial is running, AI changes the economics of monitoring. Risk-based monitoring, in which scrutiny is concentrated on the sites and data elements most likely to harbour errors, depends on recognising patterns across thousands of simultaneous data streams—precisely the task that anomaly-detection algorithms perform well. Centralised statistical monitoring can flag sites whose data distributions deviate from the norm, whether because of fraud, systematic measurement error or simple process breakdown, without the cost of sending monitors to every site on a fixed schedule. Automated adverse-event signal detection can surface safety trends earlier in the data stream, shortening the interval between an emerging risk and a protocol response. Speech-recognition and summarisation models are increasingly used to draft clinical notes, assist with adjudication of endpoints that require expert review, and reduce the administrative burden that currently consumes a large share of investigator time. Because the marginal cost of applying a trained model to new data is close to zero, these efficiencies can scale across an entire portfolio rather than applying to a single study.

The pharmaceutical industry’s interest follows directly from the arithmetic. Industry analyses have repeatedly estimated that bringing a new drug to market costs on the order of one to two billion dollars, with clinical development accounting for the majority of that expenditure and with most of the cost attributable to failed trials. Even a modest improvement in the probability of technical success, achieved through better target-patient matching or earlier detection of futility, translates into hundreds of millions of dollars in expected savings per programme and, more importantly, into faster access for patients to therapies that work. Every month shaved from a development timeline extends the effective patent-protected market life of a medicine, which strengthens the commercial case, but the public-health case is at least as strong: pipelines that iterate faster can respond more quickly to emerging pathogens, to rare diseases that currently have no treatment at all, and to the individualisation of therapy in fields such as oncology where one-size-fits-all efficacy is the exception rather than the rule.

None of this means the transformation is automatic. Machine-learning models inherit the biases of the data on which they are trained, and clinical datasets under-represent precisely the populations in whom trial evidence is weakest. An algorithm trained mostly on data from large academic hospitals may perform poorly for patients managed in community settings, and a recruitment tool optimised narrowly for speed could worsen enrolment diversity if fairness constraints are not built in explicitly. The opacity of complex models also sits awkwardly with regulatory expectations: a sponsor that uses an AI-derived covariate in a statistical analysis plan, or an AI-curated external control arm, must be able to explain to reviewers how the model was built, validated and monitored. Regulators including the United States Food and Drug Administration and the European Medicines Agency have signalled that they will evaluate such tools under existing frameworks for risk-based software validation, but the guidance landscape is still maturing, and sponsors who treat AI components as unexamined black boxes do so at their own regulatory peril.

Data governance presents a second structural challenge. The models that promise the greatest gains in recruitment and design are those trained on the largest and most diverse clinical datasets, yet health data are fragmented across institutions, jurisdictions and incompatible record systems, and privacy law constrains how they can be pooled. Federated learning, in which models are trained across multiple sites without moving the underlying patient data, offers a technically elegant partial solution, but it introduces its own questions about model ownership, auditability and the equitable distribution of the value created. Standard-setting efforts, from common data models to documented provenance for training sets, will determine whether AI-enabled trials become a broadly shared capability or a competitive advantage concentrated in a handful of organisations with the largest proprietary data estates.

The most realistic near-term picture is therefore not one of autonomous AI running trials, but of a human-machine division of labour in which algorithms perform the enumeration, matching, monitoring and simulation that humans cannot do at scale, while clinicians, statisticians and regulators retain judgment over what counts as evidence. Under that division of labour, the measurable signs of change are already visible: screening times measured in days rather than months at leading sponsors, growing numbers of adaptive and model-informed designs entering regulatory review, and decentralised, data-rich trial formats that were logistically implausible a decade ago. If those trends continue, the defining feature of the next generation of clinical trials will not be any single algorithm but the integration of computation into every stage of the evidentiary pipeline—from the first patient matching query to the final submission—producing trials that are faster, smaller where possible, larger where necessary, and ultimately more representative of the patients the resulting medicines are meant to serve.

Subject of Research: AI-enabled clinical trials

Article Title: AI-enabled clinical trials

Article References: Raynaud, M., Trayanova, N., Mannon, R. B., André, F., Doraiswamy, P. M., & Loupy, A. (2026). AI-enabled clinical trials. Nature Reviews Bioengineering. https://doi.org/10.1038/s44222-026-00487-7

Image Credits: AI Generated

DOI: 10.1038/s44222-026-00487-7

Keywords: AI-enabled, clinical, trials, scientific research, peer-reviewed research, research findings

Nosocomial infections, defined as infections acquired within hospital settings, pose a substantial risk to neonates due to their immature immune defenses, especially in neonatal intensive care units (NICUs) where preterm infants are cared for meticulously but remain highly susceptible. The NINO study sought to quantitatively assess the neurodevelopmental repercussions of such infections, integrating data across multiple centers to capture a nuanced understanding of morbidity and rehospitalization phenomena. The study’s cohort comprised infants born before 32 weeks gestational age with extremely low birth weights, whose clinical courses were extensively monitored for infectious events and subsequent neurodevelopmental milestones.

The findings unveiled a markedly elevated incidence of adverse neurodevelopmental outcomes among infants who experienced one or more nosocomial infections during their initial hospital stay. These outcomes were not limited to overt cognitive impairments but extended to complex motor and behavioral domains, as detected by standardized developmental assessments conducted at corrected ages spanning 18 to 24 months. Remarkably, the severity and multiplicity of infections appeared directly proportional to the degree of developmental deficits observed, implying a dose-dependent relationship that reinforces the critical nature of early pathogen exposure.

Further analytical layers of the study illuminated the specific types of infections most deleterious to fragile preterm infants. Bloodstream infections, predominantly driven by coagulase-negative staphylococci, and ventilator-associated pneumonias emerged as the chief culprits. These infections invariably prompted systemic inflammatory responses that, as hypothesized, may mediate neurotoxic cascades compromising brain maturation during a critical window of neuroplasticity. The role of systemic inflammation emphasizes a pathophysiological mechanism where infection transcends mere infectious morbidity to inflict lasting neurological damage.

Rehospitalization data from the NINO study provided a complementary perspective on the burden borne by these infants beyond the neonatal period. Statistical analyses demonstrated that infants suffering nosocomial infections were significantly more likely to require subsequent hospital admissions, often linked to respiratory complications, recurrent infections, and feeding difficulties. This pattern not only intensifies family distress and healthcare utilization but also flags nosocomial infection as a prognostic indicator necessitating tailored post-discharge follow-up regimens.

Clinicians and neonatologists observing these findings must grapple with the dual challenge of preventing these infections while simultaneously developing neuroprotective strategies to mitigate their impact when infections do occur. The NINO study’s rigorous methodology, encompassing comprehensive clinical data and longitudinal follow-ups, provides a robust evidence base to advocate for intensified infection control protocols within NICUs, including strict hygiene practices, judicious use of invasive devices, and antimicrobial stewardship.

Neurodevelopmental monitoring frameworks also require amplification. The study underscores the imperative for early environmental and rehabilitative interventions targeting motor skills and cognitive development, tailored for infants who have endured nosocomial infections. Integrating multidisciplinary care teams encompassing pediatric neurologists, developmental therapists, and infectious disease specialists can optimize functional outcomes and quality of life for these vulnerable patients.

Importantly, the study navigates through confounding factors such as gestational age, birth weight variability, and socioeconomic determinants, which often cloud the attribution of developmental impairments solely to infections. Employing sophisticated statistical models allowed the research team to isolate the independent effect of hospital-acquired infections, thereby strengthening the causal inference. This methodological rigor enhances the transplantability of findings to clinical guidelines and policymaking.

From a translational research viewpoint, the NINO study paves the way for investigating potential biomarkers predictive of infection-related neurodevelopmental impairment. Circulating inflammatory mediators, neurotrophic factors, and advanced neuroimaging techniques might one day enable clinicians to identify infants at greatest risk and tailor interventions with precision. Such innovations could revolutionize prognostication and bolster individualized care protocols.

Moreover, the investigation highlights the emotional and economic toll of nosocomial infections on families and healthcare systems alike. Extended hospital stays, rehospitalizations, and the need for long-term developmental support impose substantial psychosocial and financial strain. These realities underscore the broader societal implications and justify investment in preventive strategies, research, and family-centered care models.

In the evolving landscape of neonatal medicine, the NINO study constitutes a landmark contribution that decisively links nosocomial infections with enduring neurodevelopmental vulnerabilities in preterm infants with extremely low birth weight. By illuminating this perilous intersection, it galvanizes the global neonatal community to reexamine care protocols, amplify research efforts, and reinforce collaborative networks aimed at eradicating hospital-acquired infections and fostering optimal developmental trajectories.

As neonatal survival rates continue to climb thanks to medical advancements, attention must pivot towards ensuring quality of life and functional outcomes in survivorship. Studies like NINO underscore the urgency of this paradigm shift, signaling that survival alone is an insufficient endpoint. Rather, a holistic framework encompassing infection prevention, neuroprotective interventions, and comprehensive follow-up care must underpin the future of neonatal intensive care.

In conclusion, the NINO study casts a clarion call to protect the most vulnerable neonatal subgroup — preterm infants under 1500 grams — from the insidious ramifications of nosocomial infections. Its detailed elucidation of infection-related neurodevelopmental impairment and rehospitalization patterns charts a path forward, blending clinical vigilance, innovative research, and compassionate care to transform outcomes. Through such dedicated efforts, the promise of healthier beginnings may be realized for countless premature infants worldwide, securing the foundation of their lifelong health and development.

Subject of Research:
The impact of nosocomial (hospital-acquired) infections on neurodevelopmental outcomes and rehospitalization rates in preterm infants with birth weight below 1500 grams.

Article Title:
Impact of nosocomial infections on neurodevelopmental outcome and rehospitalization rate in preterm infants with birth weight below 1500 g (NINO study).

Article References:
Resch-Poteralski, E., Maurer-Fellbaum, U., Eichberger, J. et al. Impact of nosocomial infections on neurodevelopmental outcome and rehospitalization rate in preterm infants with birth weight below 1500 g (NINO study). J Perinatol (2026). https://doi.org/10.1038/s41372-026-02681-2

Image Credits: AI Generated

DOI: 10.1038/s41372-026-02681-2

In the complex and multi-staged process of metastasis, termed the invasion-metastasis cascade, the initiation hinges on the ability of primary tumor cells to dissociate from their original environment. EMT serves as the molecular switch that transforms immobile epithelial cells, characterized by tight intercellular adhesions and polarity, into mesenchymal-like cells capable of movement and invasion. This transition entails a dramatic remodeling of cellular architecture—downregulation of E-cadherin and other adhesion molecules alongside cytoskeletal rearrangement—thereby diminishing cell-cell adhesion and enabling detachment from the primary tumor mass.

Following detachment, these hybrid mesenchymal cancer cells possess the enhanced enzymatic machinery necessary to degrade the basement membrane and the extracellular matrix (ECM), clearing a path for local invasion. One pivotal axis involves the upregulation of matrix metalloproteinases (MMPs), notably MMP-7 and MMP-9, through signaling pathways such as ERK1/2 activated by molecules like Gab2. This proteolytic onslaught facilitates tumor cell infiltration beyond the epithelial boundaries into surrounding stromal tissues, a critical prelude to metastatic seeding.

As the invasion progresses, EMT also mediates the crucial transendothelial migration known as intravasation. The permeability of local vasculature is augmented through mechanisms involving the transfer of specific microRNAs—miR-27b-3p via exosomes—to endothelial cells, weakening intercellular junctions. Concurrently, hypoxic conditions within the tumor microenvironment elevate stabilization of hypoxia-inducible factor 1-alpha (HIF-1α), which in turn promotes expression of EMT transcription factors like TWIST, driving cancer cell motility essential for vessel penetration.

The tumor microenvironment itself plays a pivotal role in sustaining and amplifying EMT signals. Crosstalk between CRC cells and stromal constituents, including immune cells and fibroblasts, establishes a milieu rich in cytokines and chemokines. This dynamic ecosystem continuously feeds EMT-promoting stimuli, creating a positive-feedback loop that intensifies invasive characteristics. Additionally, environmental stressors such as low oxygen tension, inflammatory mediators, and nutrient scarcity induce metabolic rewiring in tumor cells. A notable metabolic adaptation involves a shift towards glycolysis, often referred to as the Warburg effect, which furnishes the bioenergetic and biosynthetic requirements to support aggressive proliferation and migration.

Intravasation deposits cancer cells into the bloodstream as circulating tumor cells (CTCs), where survival becomes an acute challenge due to physical shear forces, immune attacks, and detachment-triggered apoptosis known as anoikis. Herein, EMT endows CTCs with essential survival advantages by altering adhesion dynamics and modulating anti-apoptotic pathways. These transformed cells express a repertoire of adhesion molecules that facilitate their arrest onto and eventual exit from distant vascular beds in a process termed extravasation, seeding future metastatic colonies.

Interestingly, the establishment of metastases often involves a remarkable phenotypic reversal known as mesenchymal-epithelial transition (MET). While EMT aids the initial dissemination by fostering mobility, MET helps cancer cells re-adopt epithelial properties conducive to proliferation and organized growth within new tissue niches. This phenotypic plasticity is critical for metastatic colonization and underscores the dynamic nature of cellular identity during cancer progression.

Beyond its classical roles, EMT is intricately linked with the emergence of cancer stem cell (CSC)-like traits in CRC. EMT imparts stemness characteristics such as self-renewal capacity and multipotency, contributing to therapeutic resistance and tumor recurrence. This multifaceted functionality underscores EMT’s influence beyond migration, embedding itself deeply into tumor biology and progression dynamics.

The metabolic reprogramming observed in EMT-driven CRC cells is not merely a survival adaptation but an integral facilitator of metastatic competence. Enhanced glycolysis, often upregulated in hypoxic and inflammatory microenvironments, provides intermediates for anabolic processes vital for growth and invasiveness. This coordinated metabolic and phenotypic shift exemplifies the cancer cell’s adaptability to hostile environments, allowing metastatic cells to thrive where normal cells would perish.

Furthermore, microbial factors such as Fusobacterium nucleatum exacerbate EMT-mediated progression by fostering pro-angiogenic environments and inducing immune-modulatory structures like neutrophil extracellular traps. These extrinsic influences integrate with intrinsic molecular changes to potentiate invasive and migratory behavior in CRC cells.

Given the profound involvement of EMT in CRC metastasis, targeting the EMT program presents an attractive therapeutic avenue. Current strategies are exploring inhibitors of EMT-inducing pathways, modulation of the tumor microenvironment, and metabolic vulnerabilities unique to EMT-transformed cells. However, therapeutic intervention must consider the plasticity and reversibility characteristic of EMT to avoid undesired effects on normal tissue homeostasis.

In sum, EMT stands as a master regulator in the metastatic cascade of colorectal cancer, orchestrating morphological, molecular, and metabolic transformations that culminate in dissemination and colonization of distant organs. Understanding this complex transition at a mechanistic level reveals myriad molecular targets and illuminates potential pathways to intercept CRC metastasis, advancing the prospects for improving patient outcomes in this deadly malignancy.

Subject of Research:
Epithelial-mesenchymal transition in colorectal cancer metastasis and progression

Article Title:
Epithelial-mesenchymal transition in colorectal cancer metastasis and progression: molecular mechanisms and therapeutic strategies

Article References:
Nie, F., Sun, X., Sun, J. et al. Epithelial-mesenchymal transition in colorectal cancer metastasis and progression: molecular mechanisms and therapeutic strategies. Cell Death Discov. 11, 336 (2025). https://doi.org/10.1038/s41420-025-02593-8

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41420-025-02593-8